Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
161 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides an overview of the Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline landscape. Hospital Acquired Pneumonia (HAP) is defined as pneumonia acquired during hospital stay. Symptoms include cough, fever, shaking chills, confusion, headache and loss of appetite. Risk factors include chronic lung disease, cigarette smoking, dementia, stroke, brain injury, heart disease, liver cirrhosis and diabetes mellitus. Treatment includes antibiotics and healthy lifestyle. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease) The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 7, 12, 1 and 1 respectively. Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP) (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hospital Acquired Pneumonia (HAP) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP) (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hospital Acquired Pneumonia (HAP) (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hospital Acquired Pneumonia (HAP) - Overview 7 Hospital Acquired Pneumonia (HAP) - Therapeutics Development 8 Pipeline Overview 8 Pipeline by Companies 9 Products under Development by Companies 12 Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 16 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 24 Achaogen Inc 24 Adenium Biotech ApS 24 Aridis Pharmaceuticals LLC 25 AstraZeneca Plc 25 Bayer AG 26 Cardeas Pharma Corp 26 Destiny Pharma Ltd 27 Dong-A Socio Holdings Co Ltd 27 Lakewood-Amedex Inc 28 MedImmune LLC 28 Meiji Seika Pharma Co Ltd 29 Melinta Therapeutics Inc 29 Merck & Co Inc 30 Motif Bio Plc 30 Nabriva Therapeutics AG 31 Polyphor Ltd 31 Sealife PHARMA GMBH 32 Shionogi & Co Ltd 32 Tetraphase Pharmaceuticals Inc 33 The Medicines Company 33 Theravance Biopharma Inc 34 Wockhardt Ltd 34 Zavante Therapeutics Inc 35 Hospital Acquired Pneumonia (HAP) - Drug Profiles 36 (amikacin sulfate + fosfomycin) - Drug Profile 36 (avibactam + ceftazidime) - Drug Profile 38 (avibactam sodium + aztreonam lysine) - Drug Profile 43 (cefepime + zidebactam) - Drug Profile 45 (ceftolozane sulfate + tazobactam sodium) - Drug Profile 46 (cilastatin sodium + imipenem + relebactam) - Drug Profile 51 (meropenem+ vaborbactam) - Drug Profile 53 AA-139 - Drug Profile 57 Aerucin - Drug Profile 58 alalevonadifloxacin - Drug Profile 60 amikacin sulfate - Drug Profile 61 arbekacin - Drug Profile 63 ASN-100 - Drug Profile 64 cefiderocol - Drug Profile 67 delafloxacin meglumine - Drug Profile 71 EBX-004 - Drug Profile 80 eravacycline - Drug Profile 81 exeporfinium chloride - Drug Profile 88 fosfomycin tromethamine - Drug Profile 90 iclaprim mesylate - Drug Profile 93 lefamulin acetate - Drug Profile 98 levonadifloxacin - Drug Profile 103 MEDI-3902 - Drug Profile 104 Mul-1867 - Drug Profile 105 murepavadin - Drug Profile 107 Nu-2 - Drug Profile 109 Nu-3 - Drug Profile 110 Panaecin - Drug Profile 112 panobacumab - Drug Profile 113 plazomicin sulfate - Drug Profile 115 POL-7001 - Drug Profile 123 Qn-2251 - Drug Profile 124 SLP-0905 - Drug Profile 125 sodium hypochlorite - Drug Profile 126 suvratoxumab - Drug Profile 127 tedizolid phosphate - Drug Profile 128 telavancin hydrochloride - Drug Profile 136 tosatoxumab - Drug Profile 141 Viritron VDX - Drug Profile 143 Hospital Acquired Pneumonia (HAP) - Dormant Projects 144 Hospital Acquired Pneumonia (HAP) - Discontinued Products 145 Hospital Acquired Pneumonia (HAP) - Product Development Milestones 146 Featured News & Press Releases 146 Appendix 157 Methodology 157 Coverage 157 Secondary Research 157 Primary Research 157 Expert Panel Validation 157 Contact Us 157 Disclaimer 158
List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Companies, H2 2017 (Contd..3), H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Bayer AG, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Destiny Pharma Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Lakewood-Amedex Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune LLC, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Polyphor Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Sealife PHARMA GMBH, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Shionogi & Co Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by The Medicines Company, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Theravance Biopharma Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Wockhardt Ltd, H2 2017 Hospital Acquired Pneumonia (HAP) - Pipeline by Zavante Therapeutics Inc, H2 2017 Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2017 Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
